Literature DB >> 10840826

HPA-1, 3, 5 genotyping to establish a typed platelet donor panel.

J Verran1, D Grey, J Bennett, J A Lown, W N Erber.   

Abstract

Platelet antigen typing of blood donors is not routinely performed. Usually, ABO-matched platelets are transfused. In situations where the recipient has a human platelet-associated (HPA) antibody resulting in refractoriness to platelet transfusions, post-transfusion purpura or neonatal alloimmune thrombocytopenia, HPA-typed platelets may be required. Having a panel of HPA-typed donors would be helpful. This study utilised PCR-RFLP and PCR-SSP methods to determine the HPA-1, 3, 5 genotypes of 1,000 blood donors to establish a panel of HPA homozygous donors who could donate platelets for patients with anti-HPA-antibodies. The study demonstrates the HPA genotype frequencies in a Western Australian blood donor population and has identified donors who are homozygous for the "aa" and "bb" genotypes for HPA-1, 3 and 5. The Australian Red Cross Blood Service-NW Region can now use these data to develop a panel of HPA-1, 3 and 5 "aa" and "bb" homozygous platelet donors, which can be accessed for patients with HPA antibodies requiring platelet transfusion.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10840826     DOI: 10.1080/003130200104295

Source DB:  PubMed          Journal:  Pathology        ISSN: 0031-3025            Impact factor:   5.306


  2 in total

Review 1.  Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management.

Authors:  Julie A Peterson; Janice G McFarland; Brian R Curtis; Richard H Aster
Journal:  Br J Haematol       Date:  2013-02-06       Impact factor: 6.998

2.  Human Platelet Antigens in Brazilian Multiethnic Populations: Occurrence of Regional Variation and Frequency in a Large Urban Center (Belo Horizonte).

Authors:  Maria Clara Fernandes Silva-Malta; Lucas Gabriel Tavares de Oliveira; Luísa Ferreira Barreiros; Dilson Rocha do Amaral; Marina Lobato Martins
Journal:  Transfus Med Hemother       Date:  2018-05-11       Impact factor: 3.747

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.